A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary Immunodeficiency
Phase: PHASE4
Conditions: Primary Immunodeficiency
Sponsor: Grifols Therapeutics LLC

 O ﬃ ci al  Titl e :    
 A  M ul � -c e nt er,  Si n gl e -S e q u e n c e,  O p e n -l a b el  St u d y t o  E v al u at e I G S C  2 0 % 
 Bi w e e kl y  D osi n g i n  Tr e at m e nt -E x p eri e n c e d  S u bj e cts  a n d   
 L o a di n g / M ai nt e n a n c e  D osi n g i n  Tr e at m e nt -N a ïv e  S u bj e cts  wit h  Pri m ar y    
 I m m u n o d e ﬁ ci e n c y 
 N C T  N u m b er:        
 N C T 0 4 5 6 6 6 9 2  
 D o c u m e nt  D at e:  
  Pr ot o c ol V ersi o n  1. 0 : 1 7  M ar c h  2 0 2 0